Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
RMD Open
.
2023 Aug;9(3):e003435.
doi: 10.1136/rmdopen-2023-003435.
Authors
Faten Aqeel
1
,
Reza Zonozi
2
3
,
Anushya Jeyabalan
2
3
,
Gabriel Sauvage
4
,
John L Niles
4
,
Duvuru Geetha
5
Affiliations
1
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
2
Vasculitis and Glomerulonephritis Center, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
3
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
4
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
5
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA dgeetha1@jhmi.edu.
PMID:
37640515
PMCID:
PMC10462954
DOI:
10.1136/rmdopen-2023-003435
No abstract available
Keywords:
COVID-19; Systemic vasculitis; Vaccination.
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Aniline Compounds
COVID-19*
Humans
Nipecotic Acids
Substances
avacopan
Aniline Compounds
Nipecotic Acids